Literature DB >> 25126288

The working patient with cancer: implications for payers and employers.

Grant D Lawless1.   

Abstract

Cancer is seen today more often as a manageable chronic disease, resulting in changing workplace characteristics of the patient with cancer. A growing number of employees continue to work while being treated for cancer or return to work shortly after their cancer treatment is completed. To respond to these changes and the potential impact on the working patient's attitude, employers need updated, factual information related to this patient population. This type of information will support future benefit considerations by employers on employee contributions and future employee health and productivity. In 2005, Amgen launched a 3-year initiative to better understand cancer as a chronic disease, as well as the impact on the working patient with cancer and on the employer. The data from this initiative described in this article provide insights into cancer as a chronic and manageable disease in the workforce, and the broader implications to payers and employers.

Entities:  

Year:  2009        PMID: 25126288      PMCID: PMC4106533     

Source DB:  PubMed          Journal:  Am Health Drug Benefits        ISSN: 1942-2962


  4 in total

1.  Benefit design and specialty drug use.

Authors:  Dana P Goldman; Geoffrey F Joyce; Grant Lawless; William H Crown; Vincent Willey
Journal:  Health Aff (Millwood)       Date:  2006 Sep-Oct       Impact factor: 6.301

2.  Beyond the myths: finding benefit design solutions that address the true costs of high healthcare use.

Authors:  Vincent J Willey; Frank Kopenski; Grant D Lawless
Journal:  Am J Manag Care       Date:  2008-07       Impact factor: 2.229

3.  Costs of severely ill members and specialty medication use in a commercially insured population.

Authors:  Vincent J Willey; Michael F Pollack; Wayne M Lednar; William N Yang; Charles Kennedy; Grant Lawless
Journal:  Health Aff (Millwood)       Date:  2008 May-Jun       Impact factor: 6.301

4.  Symptoms and treatment burden associated with cancer treatment: results from a cross-sectional national survey in the U.S.

Authors:  David H Henry; Hema N Viswanathan; Eric P Elkin; Shana Traina; Shawn Wade; David Cella
Journal:  Support Care Cancer       Date:  2008-01-17       Impact factor: 3.603

  4 in total
  2 in total

1.  The cost burden of oral, oral pharyngeal, and salivary gland cancers in three groups: commercial insurance, Medicare, and Medicaid.

Authors:  Jed J Jacobson; Joel B Epstein; Frederick C Eichmiller; Teresa B Gibson; Ginger S Carls; Emily Vogtmann; Shaohung Wang; Barbara Murphy
Journal:  Head Neck Oncol       Date:  2012-04-26

Review 2.  Economic analysis of the breast cancer screening program used by the UK NHS: should the program be maintained?

Authors:  Robert Morton; Meelad Sayma; Manraj Singh Sura
Journal:  Breast Cancer (Dove Med Press)       Date:  2017-03-24
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.